A postmarketing safety programme for generic ticlopidine is being considered by the US FDA

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 1999年 / 753卷 / 1期

关键词：

Public Health; Neutropenia; Thrombocytopenia; Monitoring Programme; Purpura;

D O I：

10.2165/00128415-199907530-00001

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：2 / 2

相关论文

共 50 条

[11] US FDA approves first generic naloxone spray
[J]. Reactions Weekly, 2019, 1750 (1) : 7 - 7
[12] US FDA backs safety of triazolam
[J]. Reactions Weekly, 1997, 682 (1) : 2 - 2
[13] US FDA reviewing safety of orlistat
[J]. Reactions Weekly, 2009, 1267 (1) : 3 - 3
[14] US FDA reviewing safety of cefepime
[J]. Reactions Weekly, 2007, 1179 (1) : 5 - 5
[15] US FDA reviews safety of Stalevo
[J]. Reactions Weekly, 2010, 1297 (1) : 2 - 2
[16] US FDA strengthens isotretinoin risk management programme
[J]. Reactions Weekly, 2005, 1065 (1) : 3 - 3
[17] New US Digital Copyright legislation is being considered
Schultz, Eugene
[J]. COMPUTERS & SECURITY, 2006, 25 (05) : 320 - 321
[18] A proposal for financing postmarketing drug safety studies by augmenting FDA user fees
Carpenter, D
[J]. HEALTH AFFAIRS, 2005, 24 (06) : W5469 - W5480
[19] An Evaluation of Postmarketing Reports with an Outcome of Death in the US FDA Adverse Event Reporting System
Kathryn Marwitz
S. Christopher Jones
Cindy M. Kortepeter
Gerald J. Dal Pan
Monica A. Muñoz
[J]. Drug Safety, 2020, 43 : 457 - 465
[20] An Evaluation of Postmarketing Reports with an Outcome of Death in the US FDA Adverse Event Reporting System
Marwitz, Kathryn
Jones, S. Christopher
Kortepeter, Cindy M.
Dal Pan, Gerald J.
Munoz, Monica A.
[J]. DRUG SAFETY, 2020, 43 (05) : 457 - 465

← 1 2 3 4 5 →